Immunocore vs Vir Biotechnology
IMCR and VIR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMCR and VIR compare
Immunocore and Vir Biotechnology are about the same size, with market caps of $1.5B and $1.7B.
Vir Biotechnology grew revenue faster over the last twelve months (1696% versus 13.1% for Immunocore).
Immunocore keeps more of each dollar of sales as profit, with a net margin of −7.5% compared with −61.0% at Vir Biotechnology.
Vir Biotechnology scores higher on the StockData Score (12 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMCR | VIR |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $1.7B |
| Share price | $29.94 | $9.96 |
| Change, 1 year | −15.2% | 74.4% |
| Change, 5 years | −21.4% | −69.6% |
| Beta (5Y) | 0.69 | 0.72 |
| Employees | 524 | 367 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× (better) | 5.6× |
| P/B | 3.7× | 1.9× (better) |
| FCF yield | −1.2% (better) | −8.4% |
| Fair value | $31.07 | $12.60 |
| Margin of safety | 3.6% | 21.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.1% | 1696% (better) |
| Revenue growth, 5Y average | – | −2.1% |
| Profitability | ||
| Gross margin | 98.9% | – |
| Operating margin | −6.8% (better) | −69.8% |
| Net margin | −7.5% (better) | −61.0% |
| FCF margin | −4.2% (better) | −46.8% |
| Return on equity | −7.9% (better) | −21.8% |
| Return on invested capital | – | −45.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −2.4× | – |
| Current ratio | 4.62 | 6.30 (better) |
| Altman Z-score | 1.45 | 3.11 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 86.6% |
| Held by insiders | 15.5% | 17.0% |
| Insider net buying, 12 months | −$1.9M (better) | −$4.0M |
| Short interest, % of float | – | 12.0% |
Go deeper
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
- VIR stock overview
- VIR income statement
- VIR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.